MONOCLONAL ANTIBODY HAVING NEUTRALIZING ACTIVITY AGAINST MMP13
    1.
    发明申请
    MONOCLONAL ANTIBODY HAVING NEUTRALIZING ACTIVITY AGAINST MMP13 失效
    具有对MMP13的中和活性的单克隆抗体

    公开(公告)号:US20100330092A1

    公开(公告)日:2010-12-30

    申请号:US12668201

    申请日:2008-07-08

    摘要: A neutralizing monoclonal antibody specifically reacting with MMP13, a method of neutralizing enzyme activity of MMP13 and an immunological measuring method each using the antibody, as well as a diagnostic agent and a pharmaceutical composition containing the antibody, are provided. Various antibodies to MMP13 have been hitherto obtained, but an antibody having neutralizing activity against MMP13 has not been obtained. The present inventors intensively studied, as a result, found out a neutralizing antibody having specificity for MMP13, resulting in completion of the present invention.

    摘要翻译: 提供了与MMP13特异性反应的中和单克隆抗体,中和MMP13的酶活性的方法和各自使用该抗体的免疫学测定方法,以及含有该抗体的诊断剂和药物组合物。 迄今为止已经获得了MMP13的各种抗体,但是尚未获得具有针对MMP13的中和活性的抗体。 本发明人深入研究了结果,发现了对MMP13具有特异性的中和抗体,从而完成了本发明。

    Monoclonal antibody having neutralizing activity against MMP13
    2.
    发明授权
    Monoclonal antibody having neutralizing activity against MMP13 失效
    具有针对MMP13的中和活性的单克隆抗体

    公开(公告)号:US08536313B2

    公开(公告)日:2013-09-17

    申请号:US12668201

    申请日:2008-07-08

    摘要: A neutralizing monoclonal antibody specifically reacting with MMP13, a method of neutralizing enzyme activity of MMP13 and an immunological measuring method each using the antibody, as well as a diagnostic agent and a pharmaceutical composition containing the antibody, are provided. Various antibodies to MMP13 have been hitherto obtained, but an antibody having neutralizing activity against MMP13 has not been obtained. The present inventors intensively studied, as a result, found out a neutralizing antibody having specificity for MMP13, resulting in completion of the present invention.

    摘要翻译: 提供了与MMP13特异性反应的中和单克隆抗体,中和MMP13的酶活性的方法和各自使用该抗体的免疫学测定方法,以及含有该抗体的诊断剂和药物组合物。 迄今为止已经获得了MMP13的各种抗体,但是尚未获得具有针对MMP13的中和活性的抗体。 本发明人深入研究了结果,发现了对MMP13具有特异性的中和抗体,从而完成了本发明。

    COLLAGEN NEOEPITOPE ANTIBODY
    3.
    发明申请
    COLLAGEN NEOEPITOPE ANTIBODY 审中-公开
    COLLAGEN NEOEPITOPE抗体

    公开(公告)号:US20120237948A1

    公开(公告)日:2012-09-20

    申请号:US13496483

    申请日:2010-09-16

    摘要: The present invention provides a novel monoclonal antibody that is specific for a C-terminal neoepitope of a collagen fragment and has substantially equal binding affinity whether proline contained in the neoepitope is in a non-hydroxylated form or in a hydroxylated form, and an immunoassay, a measurement method, a kit and the like using the antibody. The antibody allows for quantification of a collagen fragment generated by digestion of a biological sample with a collagenase present in the sample, regardless of the presence or absence of a hydroxylated form of proline in the neoepitope.

    摘要翻译: 本发明提供了一种对胶原片段的C末端新表皮特异的新型单克隆抗体,并且具有与新表皮中所含的脯氨酸为非羟基化形式或羟基化形式的免疫测定相同的结合亲和力, 使用抗体的测定方法,试剂盒等。 抗体允许通过用存在于样品中的胶原酶消化生物样品而产生的胶原片段进行定量,而不管新表皮中是否存在羟基化形式的脯氨酸。

    Novel modified galectin 9 proteins and use thereof
    8.
    发明申请
    Novel modified galectin 9 proteins and use thereof 有权
    新型改良的半乳凝素9蛋白及其用途

    公开(公告)号:US20100203628A1

    公开(公告)日:2010-08-12

    申请号:US11547091

    申请日:2005-03-29

    摘要: It is suggested that recombinant galectin 9 (rGal 9), produced in host Escherichia coli, exhibits an immune system-mediated action and a direct action on tumor cells (i.e., activity of inducing the intercellular adhesion and apoptosis of the tumor cells), thereby potent in inducing the inhibition of cancer metastasis and reduction. Moreover, the rGal 9 exerts no efficacy on non-activated lymphocytes but can induce apoptosis in activated T cells, in particular, CD4-positive T cells causing an excessive immune response. The rGal 9 has a further potent apoptosis-inducing property on synovial cells participating in joint deformation in rheumatism, etc. In the rGal 9, however, a link domain linking two CRDs is highly susceptible to protease and, therefore, is very easily digestible with the enzyme, thereby losing the above activities. Thus, there is a need for a more stabilized molecule in view of further studies. Modification of the link domain linking two CRDs in galectin 9 provides a modified molecule having an elevated activity without any undesirable effects on the above activities.

    摘要翻译: 建议在宿主大肠杆菌中产生的重组半乳凝素9(rGal 9)表现出免疫系统介导的作用和对肿瘤细胞的直接作用(即,诱导肿瘤细胞的细胞间粘附和凋亡的活性),由此 有效诱导癌症转移和还原的抑​​制。 此外,rGal9对非活化淋巴细胞没有效力,但可以诱导活化的T细胞,特别是导致过度免疫应答的CD4阳性T细胞的细胞凋亡。 rGal9对参与风湿病关节变形的滑膜细胞具有更强的细胞凋亡诱导性质。然而,在rGal9中,连接两个CRD的连接域对蛋白酶非常敏感,因此很容易被消化 该酶,从而失去上述活性。 因此,鉴于进一步研究,需要更稳定的分子。 连接半乳凝素9中两个CRD的连接结构域的修饰提供了具有升高活性的修饰分子,而对上述活性没有任何不良影响。

    THERMOPLASTIC ELASTOMERIC COMPOSITION
    10.
    发明申请
    THERMOPLASTIC ELASTOMERIC COMPOSITION 审中-公开
    热塑性弹性体组合物

    公开(公告)号:US20090124746A1

    公开(公告)日:2009-05-14

    申请号:US12090820

    申请日:2006-10-18

    IPC分类号: C08K3/04

    摘要: A thermoplastic elastomeric composition which have an improved compression set and good electrical properties is provided.The disclosed is thermoplastic elastomeric composition which includes 0.1-30 parts by weight of carbon fibrous structures per 100 parts by weight of a thermoplastic elastomer, wherein the carbon fibrous structure comprises a three dimensional network of carbon fibers each having an outside diameter of 15-100 nm, wherein the carbon fibrous structure further comprises a granular part with which the carbon fibers are tied together in the state that the concerned carbon fibers are externally elongated therefrom, and wherein the granular part is produced in a growth process of the carbon fibers.

    摘要翻译: 提供了具有改进的压缩永久变形和良好电性能的热塑性弹性体组合物。 所公开的是热塑性弹性体组合物,其包含每100重量份热塑性弹性体0.1-30重量份的碳纤维结构,其中碳纤维结构包括三维网状碳纤维,每个纤维网的外径为15-100 nm,其中所述碳纤维结构还包括在所述碳纤维从其外部延伸的状态下将所述碳纤维捆扎在一起的颗粒部分,并且其中所述颗粒部分在所述碳纤维的生长过程中产生。